Metrics

  • citations in SCIndeks: 0
  • citations in CrossRef:0
  • citations in Google Scholar:[]
  • visits in previous 30 days:102
  • full-text downloads in 30 days:15

Contents

article: 7 from 361  
Back back to result list
2021, vol. 71, iss. 2, pp. 101-119
Safety and efficacy of interleukin inhibitors in elderly patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis
aUniversity of Belgrade, Faculty of Pharmacy
bUniversity of Belgrade, Faculty of Pharmacy, Institute of Microbiology and Immunology

emailjasmina@pharmacy.bg.ac.rs
Keywords: interleukin inhibitors; elderly patients; safety; efficacy
Abstract
Elderly patients with rheumatoid arthritis, psoriasis and psoriatic arthritis encompass those with elderly-onset disease, over 60 years of age, but also those with earlier disease onset who entered old age. Considering the age-related changes of the immune system, possible frailty, susceptibility to infection and concomitant comorbidity that implies multiple medicines, the treatment of these diseases in elderly patients can be challenging. Interleukin inhibitors have been shown to be an efficient and safe treatment for these diseases. However, elderly patients with these diseases were often included in the pivotal clinical trials for interleukin inhibitors in numbers insufficient to determine whether they responded differently from younger subjects. The aim of this paper was to review the findings on the efficacy and safety of interleukin inhibitor treatment in elderly patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis. The findings suggest that, for all the interleukin inhibitors reviewed herein, used in elderly patients with rheumatoid arthritis, or with psoriasis and psoriatic arthritis, the efficacy was comparable to younger patients. Furthermore, the incidence of reported adverse events was similar in these two age groups. Severe adverse events, which were related to sarilumab treatment for rheumatoid arthritis and secukinumab treatment for psoriasis, were higher in elderly patients. The reviewed findings suggest that the interleukin inhibitors approved and currently in use in clinical practice for the treatment of rheumatoid arthritis, psoriasis, and psoriatic arthritis can be considered a safe and efficient option for these diseases in elderly patients.
References
*** P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis (AMAGINE-2). [cited 2021 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT01708603?term=brodalumab%2C+AMAGINE-2&draw=2
*** Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3). [cited 2021 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT01708629?term=brodalumab%2C+AMAGINE-3&draw=2&rank=1
*** A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants with Psoriatic Arthritis (PsaBio). [cited 2021 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT02627768
Aitken, A.E., Morgan, E.T. (2007) Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human Hepatocytes. Drug Metabolism and Disposition, 35(9): 1687-1693
Allen, M.H., Ameen, H., Veal, C., Evans, J., Ramrakha-Jones, V.S., Marsland, A.M., David, B.A., Griffiths, C.E.M., Trembath, R.C., Barker, J.N.W.N. (2005) The Major Psoriasis Susceptibility Locus PSORS1 Is not a Risk Factor for Late-Onset Psoriasis. Journal of Investigative Dermatology, 124(1): 103-106
Álvarez-Rodríguez, L., López-Hoyos, M., Muñoz-Cacho, P., Martínez-Taboada, V.M. (2012) Aging is associated with circulating cytokine dysregulation. Cellular Immunology, 273(2): 124-132
Baert, F., Noman, M., Vermeire, S., van Assche, G., d' Haens, G., Carbonez, A., Rutgeerts, P. (2003) Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease. New England Journal of Medicine, 348(7): 601-608
Bakirtzi, K., Sotiriou, E., Papadimitriou, I., Sideris, N., Vakirlis, E., Lallas, A., Vrani, F., Ioannides, D. (2020) Elderly patients with psoriasis: Long-term efficacy and safety of modern treatments. Journal of Dermatological Treatment, 1-4, Epub ahead of print
Baskar, S., Klein, A.L., Zeft, A. (2016) The Use of IL-1 Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis: A Narrative Review. Cardiology Research and Practice, 2016:7840724
Boots, A.M.H., Maier, A.B., Stinissen, P., Masson, P., Lories, R.J., de Keyser, F. (2013) The influence of ageing on the development and management of rheumatoid arthritis. Nature Reviews Rheumatology, 9(10): 604-613
Boyd, C.M., Darer, J., Boult, C., Fried, L.P., Boult, L., Wu, A.W. (2005) Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: Implications for pay for performance. JAMA, 294(6): 716-724
Brembilla, N.C., Senra, L., Boehncke, W.H. (2018) The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. Frontiers in Immunology, 9: 1682-1682
Bürkle, A., Caselli, G., Franceschi, C., Mariani, E., Sansoni, P., Santoni, A., Vecchio, G., Witkowski, J.M., Caruso, C. (2007) Pathophysiology of ageing, longevity and age related diseases. Immunity & Ageing, 4(1): 4-4
Caso, F., Tasso, M., Chimenti, M.S., Navarini, L., Perricone, C., Girolimetto, N., Peluso, R., Del, P.A., Afeltra, A., Perricone, R., Punzi, L., Scarpa, R., Costa, L. (2019) Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management. Drugs & Aging, 36(10): 909-925
Compté, N., Zouaoui, B.K., Vanhaeverbeek, M., de Breucker, S., Tassignon, J., Trelcat, A., Pepersack, T., Goriely, S. (2013) Frailty in Old Age Is Associated with Decreased Interleukin-12/23 Production in Response to Toll-Like Receptor Ligation. PLoS One, 8(6): e65325-e65325
Crowley, J.J., Warren, R.B., Cather, J.C. (2019) Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology, 33(9): 1676-1684
de Spiegeleer, B., Wynendaele, E., Bracke, N., Veryser, L., Taevernier, L., Degroote, A., i dr. (2016) Regulatory development of geriatric medicines: To GIP or not to GIP?. Ageing Res Rev, 27:23-36
Denson, A.C., Mahipal, A. (2014) Participation of the Elderly Population in Clinical Trials: Barriers and Solutions. Cancer Control, 21(3): 209-214
Deodhar, A., Mease, P.J., Mcinnes, I.B., Baraliakos, X., Reich, K., Blauvelt, A., Leonardi, C., Porter, B., Das, G.A., Widmer, A., Pricop, L., Fox, T. (2019) Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: Integrated pooled clinical trial and post-marketing surveillance data. Arthritis Research & Therapy, 21(1): 111-111
di Lernia, V., Goldust, M. (2018) An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. Expert Opinion on Biological Therapy, 18(8): 897-903
Dinarello, C.A., Simon, A., van der Meer, J.W. (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov, 11(8): 633-52
European Medicines Agency Summary of product characteristics: RoActemra (tocilizumab). [cited 2021 Mar 31]. Available from: https://www.ema.europa.eu/en/documents/productinformation/roactemra-epar-product-information_en.pdf
European Medicines Agency [Internet]. [cited 2021 Mar 31]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra#authorisation-details-section
European Medicines Agency [cited 2021 Mar 31]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara#authorisation-details-section
European Medicines Agency [cited 2021 Mar 31]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/stelara#authorisation-details-section
European Medicines Agency [cited 2021 Mar 31]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx#authorisation-details-section
European Medicines Agency ICH Topic E 7 Studies in Support of Special Populations: Geriatrics. [cited 2021 Mar 31]. Available from: https://www.ema.europa.eu/en/documents/scientificguideline/ich-e-7-studies-support-special-populations-geriatrics-step-5_en.pdf
European Medicines Agency ICH topic E7 Studies in Support of Special Populations: Geriatrics Questions and Answers. [cited 2021 Mar 31]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-7-studies-support-specialpopulations-geriatrics-questions-answers-step-5_en.pdf
European Medicines Agency EMA geriatric medicines strategy. [cited 2021 Mar 31]. Available from: https://www.ema.europa.eu/en/documents/other/mandate-objectives-rules-procedure-chmpgeriatric-expert-group_en.pdf
European Medicines Agency [cited 2021 Mar 31]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-7-studies-support-specialpopulations-geriatrics-questions-answers-step-5_en.pdf
European Medicines Agency Points to consider on frailty: Evaluation instruments for baseline characterisation of clinical trial populations. [cited 2021 Mar 31]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-points-consider-frailtyevaluation-instruments-baseline-characterisation-clinical-trial_en.pdf
European Medicines Agency [cited 2021 Mar 31]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/taltz#authorisation-details-section
European Medicines Agency [cited 2021 Mar 31]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum#authorisation-details-section
Fabbri, L.M., Ferrari, R. (2006) Chronic disease in the elderly: Back to the future of internal medicine. Breathe, 3(1): 40-49
Ferri, N., Bellosta, S., Baldessin, L., Boccia, D., Racagni, G., Corsini, A. (2016) Pharmacokinetics interactions of monoclonal antibodies. Pharmacological Research, 111: 592-599
Fleischmann, R., Genovese, M.C., van Adelsberg, J., Mangan, E., Iglesias-Rodriguez, M., Dukovic, D., i dr. (2016) Pooled safety and efficacy of sarilumab in rheumatoid arthritis patients 65 years of age and older. Arthritis Rheumatol, 68(10)
Foulkes, A.C., Warren, R.B. (2019) Brodalumab in psoriasis: Evidence to date and clinical potential. Drugs in Context, 8:212570
Fraenkel, L., Rabidou, N., Dhar, R. (2006) Are rheumatologists' treatment decisions influenced by patients' age?. Rheumatology (Oxford), 45(12): 1555-1557
Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., Santoro, A. (2018) Inflammaging: A new immune-metabolic viewpoint for age-related diseases. Nature Reviews Endocrinology, 14(10): 576-590
Gladman, D.D., Antoni, C., Mease, P., Clegg, D.O., Nash, P. (2005) Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Annals of the Rheumatic Diseases, 64(suppl_2): ii14-ii17
Goetzl, E.J., Huang, M.C., Kon, J., Patel, K., Schwartz, J.B., Fast, K., i dr. (2010) Gender specificity of altered human immune cytokine profiles in aging. FASEB J, 24(9): 3580-3589
Gossec, L., Theander, E., Chakravarty, S., Bergmans, P., Lin, I., Noël, W., i dr. (2020) Ustekinumab-Treated Patients with Psoriatic Arthritis in a Real-world Study: Similar Clinical Responses and Treatment Persistence over One Year in Elderly and Younger Patients. Arthritis Rheumatol
Guo, Q., Wang, Y., Xu, D., Nossent, J., Pavlos, N.J., Xu, J. (2018) Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies. Bone Research, 27;6:15
Haroon, M., Kirby, B., Fitzgerald, O. (2013) High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Annals of the Rheumatic Diseases, 72(5): 736-740
Hayashi, M., Umezawa, Y., Fukuchi, O., Ito, T., Saeki, H., Nakagawa, H. (2014) Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. Journal of Dermatology, 41(11): 974-980
Hébert, H.L., Bowes, J., Smith, R.L., McHugh, N.J., Barker, J.N.W.N., Griffiths, C.E.M., Barton, A., Warren, R.B. (2014) Polymorphisms in IL-1B Distinguish between Psoriasis of Early and Late Onset. Journal of Investigative Dermatology, 134(5): 1459-1462
Hempenius, L., Slaets, J.P.J., Boelens, M.A.M., van Asselt, D.Z.B., de Bock, G.H., Wiggers, T., van Leeuwen, B.L. (2013) Inclusion of frail elderly patients in clinical trials: Solutions to the problems. Journal of Geriatric Oncology, 4(1): 26-31
Huscher, D., Sengler, C., Gromnica-Ihle, E., Bischoff, S., Eidner, T., Ochs, W., i dr. (2013) Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: A matched-pairs analysis taking age and disease duration into account. Clin Exp Rheumatol, 31(2): 256-62
Innala, L., Berglin, E., Möller, B., Ljung, L., Smedby, T., Södergren, A., Magnusson, S., Rantapää-Dahlqvist, S., Wållberg-Jonsson, S. (2014) Age at onset determines severity and choice of treatment in early rheumatoid arthritis: A prospective study. Arthritis Research & Therapy, 16(2): R94-R94
Jeon, C., Sekhon, S., Yan, D., Afifi, L., Nakamura, M., Bhutani, T. (2017) Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. Human Vaccines & Immunotherapeutics, 13(10): 2247-2259
Jin, W., Dong, C. (2013) IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect, 2(9): 60-60
June, R.R., Olsen, N.J. (2016) Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy, 16(10): 1303-1309
Kamata, M., Tada, Y. (2020) Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. International Journal of Molecular Sciences, 21(5): 1690-1690
Khatsenko, O.G., Gross, S.S., Rifkind, A.B., Vane, J.R. (1993) Nitric oxide is a mediator of the decrease in cytochrome P450-dependent metabolism caused by immunostimulants. Proceedings of the National Academy of Sciences, 90(23): 11147-11151
Kievit, W., van Hulst, L., van Riel, P., Fraenkel, L. (2010) Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: Results from a choice-based conjoint analysis. Arthritis Care & Research (Hoboken), 62(6): 842-847
Kim, G.K., Del, R.J.Q. (2010) Drug-provoked psoriasis: Is it drug induced or drug aggravated? Understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol, 3(1): 32-40
Kim, W.B., Jerome, D., Yeung, J. (2017) Diagnosis and management of psoriasis. Can Fam Physician, 63(4): 278-285
Kobak, S., Bes, C. (2018) An autumn tale: Geriatric rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 10(1): 3-11
Körber, A., Papavassilis, C., Bhosekar, V., Reinhardt, M. (2018) Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies. Drugs & Aging, 35(2): 135-144
Kwon, H.H., Kwon, I.H., Youn, J.I. (2012) Clinical study of psoriasis occurring over the age of 60 years: Is elderly-onset psoriasis a distinct subtype?. International Journal of Dermatology, 51(1): 53-58
Lebwohl, M., Menter, A., Yamauchi, P., Wu, J.J., Lin, T. (2019) Brodalumab in patients with psoriasis ages <65 and 65 years: 120-week findings from two phase 3 studies. Journal of the American Academy of Dermatology, 81(4): AB176-AB176
Lee, J.S., Lee, W.S., Kim, S.H., Kang, Y., Lee, N.S., Shin, M.S., Kang, S.W., Kang, I. (2011) Age-associated alteration in naive and memory Th17 cell response in humans. Clinical Immunology, 140(1): 84-91
Liu, L., Kikly, K., Lu, J., Allan, B.W., Tang, Y., Tetreault, J., Chow, C.K., Barmettler, B., Nelson, J., Bina, H., Huang, L., Wroblewski, V. (2016) Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. Journal of Inflammation Research, 9: 39-50
Magyari, L., Varszegi, D., Kovesdi, E., Sarlos, P., Farago, B., Javorhazy, A., i dr. (2014) Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications. World Journal of Orthopedics, 5(4): 516-516
Martin, D.A., Towne, J.E., Kricorian, G., Klekotka, P., Gudjonsson, J.E., Krueger, J.G., Russell, C.B. (2013) The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings. Journal of Investigative Dermatology, 133(1): 17-26
Mcinnes, I.B., Mease, P.J., Kivitz, A.J., Nash, P., Rahman, P., Rech, J., i dr. (2020) Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. Lancet Rheumatology, 2(4): 30036-30045
Mckeage, K. (2014) Ustekinumab: A Review of Its Use in Psoriatic Arthritis. Drugs, 74(9): 1029-1039
Mease, P.J., Gladman, D.D., Papp, K.A., Khraishi, M.M., Thaçi, D., Behrens, F., Northington, R., Fuiman, J., Bananis, E., Boggs, R., Alvarez, D. (2013) Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. Journal of the American Academy of Dermatology, Nov;69(5):729-735
Megna, M., Camela, E., Cinelli, E., Fabbrocini, G. (2020) Real-life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2-year period. Clinical and Experimental Dermatology, 45(7): 848-852
Megna, M., Napolitano, M., Balato, N., Monfrecola, G., Villani, A., Ayala, F., Balato, A. (2016) Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period. Clinical and Experimental Dermatology, 41(5): 564-566
Megna, M., Cinelli, E., Balato, A., Gallo, L., Fabbrocini, G. (2020) Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period. Journal of the European Academy of Dermatology and Venereology, 34(3): 152-153
Meibohm, B. (2006) The Role of Pharmacokinetics and Pharmacodynamics in the Development of Biotech Drugs. in: Meibohm B. [ed.] Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development, Weinheim: WILEY-VCH Verlag GmbH & Co, p. 1-13
Mihara, M., Kasutani, K., Okazaki, M., Nakamura, A., Kawai, S., Sugimoto, M., Matsumoto, Y., Ohsugi, Y. (2005) Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. International Immunopharmacology, 5(12): 1731-1740
Milan-Mattos, J.C., Anibal, F.F., Perseguini, N.M., Minatel, V., Rehder-Santos, P., Castro, C.A., Vasilceac, F.A., Mattiello, S.M., Faccioli, L.H., Catai, A.M. (2019) Effects of natural aging and gender on pro-inflammatory markers. Brazilian Journal of Medical and Biological Research, 52(9): 8392-8392
Mould, D.R., Green, B. (2010) Pharmacokinetics and pharmacodynamics of monoclonal antibodies: Concepts and lessons for drug development. BioDrugs, 24(1): 23-39
Müller, L., Pawelec, G. (2015) As we age: Does slippage of quality control in the immune system lead to collateral damage?. Ageing Res Rev, 23(Pt A):116-23
Müller, L., di Benedetto, S., Pawelec, G. (2019) The immune system and its dysregulation with aging. Subcell Biochem, 91:21-43
Nikolich-Žugich, J. (2018) The twilight of immunity: Emerging concepts in aging of the immune system. Nature Immunology, 19(1), 10-19
Nikolich-Žugich, J. (2014) Aging of the T Cell Compartment in Mice and Humans: From No Naive Expectations to Foggy Memories. Journal of Immunology, 193(6): 2622-2629
Ogdie, A., Weiss, P. (2015) The Epidemiology of Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 41(4): 545-568
Olivieri, I., Palazzi, C., Peruz, G., Padula, A. (2005) Management issues with elderly-onset rheumatoid arthritis: An update. Drugs & Aging, 22(10): 809-822
Orwig, D., Rickles, N.M., Martin, L.G. (2011) Methodological Issues in Pharmacotherapy Research in Older Adults. American Journal of Geriatric Pharmacotherapy, 9(3): 173-189
Pers, Y.M., Schaub, R., Constant, E., Lambert, J., Godfrin-Valnet, M., Fortunet, C., Bourichi, W., Prades, B.P., Wendling, D., Gaudin, P., Jorgensen, C., Maillefert, J., Marotte, H. (2015) Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis. Joint Bone Spine, 82(1): 25-30
Phan, C., Sigal, M.L.L., Estève, E., Reguiai, Z., Barthélémy, H., Beneton, N., Maccari, F., Lahfa, M., Thomas-Beaulieu, D., Le, G.T., Vermersch-Langlin, A., Mery-Bossard, L., Pallure, V., Kemula, M., Labeille, B., Beauchet, A., Mahé, E. (2016) Psoriasis in the elderly: Epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. Journal of the European Academy of Dermatology and Venereology, 30(1): 78-82
Poirier, P., Giles, T.D., Bray, G.A., Hong, Y., Stern, J.S., Pi-Sunyer, F.X., Eckel, R.H., American Heart Association (2006) Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss: An update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Phy. Circulation, 113(6):898-918
Punzi, L., Pianon, M., Rossini, P., Schiavon, F., Gambari, P.F. (1999) Clinical and laboratory manifestations of elderly onset psoriatic arthritis: A comparison with younger onset disease. Annals of the Rheumatic Diseases, 58(4): 226-229
Punzi, L., Bertazzolo, N., Pianon, M., Rizzi, E., Rossini, P., Todesco, S. (1996) Synovial fluid levels of proinflammatory interleukins and their inter-relationships in elderly vs younger onset rheumatoid arthritis. Aging Clinical and Experimental Research, 8(4): 277-281
Queiro, R., Tejón, P., Alonso, S., Coto, P. (2014) Age at disease onset: A key factor for understanding psoriatic disease. Rheumatology (Oxford), 53(7): 1178-1185
Rachakonda, T.D., Schupp, C.W., Armstrong, A.W. (2014) Psoriasis prevalence among adults in the United States. Journal of the American Academy of Dermatology, 70(3): 512-516
Radovits, B.J., Fransen, J., Eijsbouts, A., van Riel, P.L.C.M., Laan, R.F.J.M. (2009) Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology (Oxford), 48(8): 906-910
Rafique, A., Martin, J., Blome, M., Huang, T., Ouyang, A., Papadopoulos, N. (2013) AB0037 Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human il-6 receptor (il-6r) Alpha. Annals of the Rheumatic Diseases, 72(Suppl 3): A797.1-A797
Rasch, E.K., Hirsch, R., Paulose-Ram, R., Hochberg, M.C. (2003) Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: Effect of different methods of case classification. Arthritis & Rheumatism, 48(4): 917-926
Reich, K. (2012) The concept of psoriasis as a systemic inflammation: Implications for disease management. Journal of the European Academy of Dermatology and Venereology, 26(2): 3-11
Rempher, K.J. (2006) Cardiovascular Sequelae of Tobacco Smoking. Critical Care Nursing Clinics of North America, 18(1): 13-20
Schmajuk, G., Schneeweiss, S., Katz, J.N., Weinblatt, M.E., Setoguchi, S., Avorn, J., Levin, R., Solomon, D.H. (2007) Treatment of older adult patients diagnosed with rheumatoid arthritis: Improved but not optimal. Arthritis & Rheumatism, 57(6): 928-934
Schmitt, C., Kuhn, B., Zhang, X., Kivitz, A.J., Grange, S. (2011) Disease-Drug-Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis. Clinical Pharmacology & Therapeutics, 89(5): 735-740
Scott, L.J. (2017) Tocilizumab: A Review in Rheumatoid Arthritis. Drugs, 77(17): 1865-1879
Sebba, A. (2008) Tocilizumab: The first interleukin-6-receptor inhibitor. American Journal of Health-System Pharmacy, 65(15): 1413-1418
Seitz, K., Zhou, G. (2007) Pharmacokinetic Drug-Drug Interaction Potentials for Therapeutic Monoclonal Antibodies: Reality Check. Journal of Clinical Pharmacology, 47(9): 1104-1118
Sera, L.C., McPherson, M.L. (2012) Pharmacokinetics and Pharmacodynamic Changes Associated with Aging and Implications for Drug Therapy. Clinics in Geriatric Medicine, 28(2): 273-286
Shenoy, P., Harugeri, A. (2015) Elderly patients' participation in clinical trials. Perspectives in Clinical Research, 6(4): 184-9
Singh, J.A., Saag, K.G., Bridges, L.S., Akl, E.A., Bannuru, R.R., Sullivan, M.C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R.H., Curtis, J.R., Furst, D.E., Parks, D. (2016) 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & Rheumatology, 68(1): 1-26
Smolen, J.S., Landewé, R.B.M., Bijlsma, J.W.J., Burmester, G.R., Dougados, M., Kerschbaumer, A., i dr. (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis, 79(6):685-699
Smolen, J.S., Aletaha, D., McInnes, I.B. (2016) Rheumatoid arthritis. Lancet, 22;388(10055):2023-2038. Erratum in: Lancet. 2016 Oct 22;388(10055):1984
Specker, C., Alberding, A., Aringer, M., Burmester, G.R., Flacke, J.P., Hofmann, M.W., i dr. (2020) ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis. Clin Exp Rheumatol, Jul 10. Epub ahead of print
Specker, C., Kaufmann, J., Kellner, H., Kästner, P., Volberg, C., Braunewell, V., Aringer, A., Sieburg, M., Meier, L., Hofmann, M.W., Flacke, J.P., Tony, H.P., Fliedner, G. (2016) FRI0202 Safe and Effective Tocilizumab Therapy in Elderly Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 75(Suppl 2): 504.1-504
Takeshita, J., Grewal, S., Langan, S.M., Mehta, N.N., Ogdie, A., van Voorhees, A.S., Gelfand, J.M. (2017) Psoriasis and comorbid diseases: Epidemiology. Journal of the American Academy of Dermatology, 76(3): 377-390
Theodorakopoulou, E., Yiu, Z.Z.N., Bundy, C., Chularojanamontri, L., Gittins, M., Jamieson, L.A., Motta, L., Warren, R.B., Griffiths, C.E.M. (2016) Earlyand late-onset psoriasis: A cross-sectional clinical and immunocytochemical investigation. British Journal of Dermatology, 175(5): 1038-1044
Treharne, G.J., Douglas, K.M.J., Iwaszko, J., Panoulas, V.F., Hale, E.D., Mitton, D.L., Piper, H., Erb, N., Kitas, G.D. (2007) Polypharmacy among people with rheumatoid arthritis: The role of age, disease duration and comorbidity. Musculoskeletal Care, 5(4): 175-190
Tsai, Y.C., Tsai, T.C. (2017) Anti-interleukin and interleukin therapies for psoriasis: Current evidence and clinical usefulness. Therapeutic Advances in Musculoskeletal Disease, 9(11): 277-294
Tsankov, N., Irena, A., Kasandjieva, J. (2000) Drug-induced psoriasis: Recognition and management. Am J Clin Dermatol, 1: 159-165
Tutuncu, Z., Reed, G., Kremer, J., Kavanaugh, A. (2006) Do patients with older-onset rheumatoid arthritis receive less aggressive treatment?. Annals of the Rheumatic Diseases, 65(9): 1226-1229
U S.Food And Drug Administration [Internet]. [cited 2021 Mar 31]. Available from: https://www.fda.gov/media/107409/download
U S.Food And Drug Administration Highlights of prescribing information: Cosentyx (secukinumab). [cited 2021 Mar 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125504s001s002lbl.pdf
U S.Food And Drug Administration Highlights of prescribing information: Siliq (brodalumab). [cited 2021 Mar 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf
U S.Food And Drug Administration Highlights of prescribing information: Taltz (ixekizumab). [cited 2021 Mar 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf
U S.Food And Drug Administration Highlights of prescribing information: Tremfya (guselkumab). [cited 2021 Mar 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761061s000lbl.pdf
U S.Food And Drug Administration Highlights of prescribing information: Ilumya (tildrakizumab). [cited 2021 Mar 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf
U S.Food And Drug Administration Highlights of prescribing information: Skyrizi (risankizumab). [cited 2021 Mar 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761105s000lbl.pdf
U S.Food And Drug Administration Highlights of prescribing information: Kineret (anakinra). [cited 2021 Mar 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103950s5136lbl.pdf
U S.Food And Drug Administration Highlights of prescribing information: Actemra (tocilizumab). [cited 2021 Mar 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf
U S.Food And Drug Administration Highlights of prescribing information: Kevzara (sarilumab). [cited 2021 Mar 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761037s000lbl.pdf
U.S. Food and Drug administration Highlights of prescribing information: Stelara (ustekinumab). [cited 2021 Mar 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761044s003lbl.pdf
United Nations-Department Of Economic And Social Affairs-Population Division (2019) World Population Prospects 2019: Highlights. ST/ESA/SER.A/423. Available from: https://population.un.org/wpp/Publications/Files/WPP2019_Highlights.pdf
van Gestel, A.M., Prevoo, M.L.L., Van't, H.M.A., van Rijswijk, M.H., van de Putte, L.B.A., van Riel, P.L.C.M. (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatis. Arthritis & Rheumatism, 39(1): 34-40
Varadhan, R., Yao, W., Matteini, A., Beamer, B.A., Xue, Q.L., Yang, H., Manwani, B., Reiner, A., Jenny, N., Parekh, N., Fallin, M.D., Newman, A., Bandeen-Roche, K., Tracy, R., Ferrucci, L., Walston, J. (2014) Simple Biologically Informed Inflammatory Index of Two Serum Cytokines Predicts 10 Year All-Cause Mortality in Older Adults. Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 69A(2): 165-173
Yang, K., Oak, A.S.W., Elewski, B.E. (2021) Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. American Journal of Clinical Dermatology, 22(2): 173-192
Zhou, H., Mascelli, M.A. (2011) Mechanisms of Monoclonal Antibody-Drug Interactions. Annual Review of Pharmacology and Toxicology, 51(1): 359-372
Zídek, Z., Anzenbacher, P., Kmoníčková, E. (2009) Current status and challenges of cytokine pharmacology. British Journal of Pharmacology, 157(3): 342-361
 

About

article language: English
document type: Review Paper
DOI: 10.5937/arhfarm71-30505
published in SCIndeks: 29/04/2021
peer review method: single-blind
Creative Commons License 4.0

Related records

Arhiv za farmaciju (2020)
Direct oral anticoagulants: A new chapter in anticoagulation therapy
Stepanović-Petrović Radica, et al.

Arhiv za farmaciju (2013)
Herbal medicinal products in dermatology
Maksimović Zoran, et al.

Arhiv za farmaciju (2019)
Herbal and traditional Herbal Medicinal Products, EU Herbal monographs and EU list
Petrović Silvana

show all [6]